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Systematic reviewBackground: Proton beam therapy (PBT) delivers high-energy radiation to target tumours while sparing
surrounding normal tissues. The dosimetric advantages of PBT over traditional photon radiotherapy may
be clear but the translation of this benefit into clinically meaningful reductions in toxicities and improved
quality-of-life (QoL) needs to be determined. Randomised controlled trials (RCTs) are considered the gold
standard for generating the highest-level evidence in medicine. The objectives of this systematic review
were to provide an overview of published clinical studies evaluating the benefits of PBT, and to examine
the methodology used in clinical trials with respect to study design and outcomes.
Methods: PubMed, EMBASE and Cochrane databases were systematically searched for published clinical
studies where PBT was a cancer treatment intervention. All randomised and non-randomised studies,
prospective or retrospective, were eligible for inclusion.
Results: In total, 219 studies were included. Prospective studies comprised 89/219 (41%), and of these, the
number of randomised phase II and III trials were 5/89 (6%) and 3/89 (3%) respectively. Of all the phase II
and III trials, 18/24 (75%) were conducted at a single PBT centre. Over one-third of authors recommended
an increase in length of follow up. Research design and/or findings were poorly reported in 74/89 (83%) of
prospective studies. Patient reported outcomes were assessed in only 19/89 (21%) of prospective studies.
Conclusions: Prospective randomised evidence for PBT is limited. The set-up of national PBT services in
several countries provides an opportunity to guide the optimal design of prospective studies, including
RCTs, to evaluate the benefits of PBT across various disease sites. Collaboration between PBT centres, both
nationally and internationally, would increase potential for the generation of practice changing evidence.
There is a need to facilitate and guide the collection and analysis of meaningful outcome data, including
late toxicities and patient reported QoL.
 2019 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).1. Introduction
Advancements in the delivery of radiotherapy require
improvements in efficacy by delivering an optimal dose to the tar-
get tumour while minimising dose to the surrounding normal tis-
sues in an effort to reduce toxicity. Standard photon radiotherapydelivers a relatively high entrance dose before depositing energy
in the target and then continuing to deposit energy beyond the tar-
get, albeit with a gradual reduction in dose. In contrast, proton
beam therapy (PBT) is an advanced radiation treatment charac-
terised by its Bragg peak, whereby a high dose is delivered to the
target, followed by an immediate drop in energy resulting in min-
imum to no exit dose compared to standard photon radiotherapy,
thereby sparing surrounding normal tissues. This phenomenon
potentially increases the therapeutic ratio.
Evidence from dosimetric and planning studies show that lower
mean radiation doses are delivered to surrounding normal tissues
using protons compared to photons in the treatment of paediatric
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gest a dosimetric advantage of PBT, it is uncertain whether this
translates into measurable clinically significant benefits for the
patient in the short and/or long term. Other concerns include range
uncertainties, organ motion, and anatomical changes of target
tumour or normal organ.
Past reviews on clinical outcomes criticise the lack of robust
evidence of the clinical superiority of protons over photons [12–
15], and the debate on the need for randomisation in clinical trials
evaluating the benefits of PBT persists [16–23]. Nevertheless,
uncertainties about the effect of protons on toxicity, tumour con-
trol, and survival, warrant prospective high quality studies. Wher-
ever possible, randomised controlled trials are recommended as
they are considered by most to be the gold standard for generating
practice changing evidence [22,24,25].
An estimated 149,345 patients were treated with protons
between 1954 and 2016 [26] and the development of new PBT cen-
tres in countries such as United Kingdom (UK), India, Australia,
Norway and Denmark suggests a global increase in treatment
uptake. Challenges in designing clinical trials for PBT include barri-
ers to enrolment such as cost coverage (by governments or third
party payers) [25], patient preference, and travel distance to PBT
centres. However, findings from studies exploring patient involve-
ment in proton trials suggest that patients would be willing to par-
ticipate in PBT trials [27,28].
This systematic review aims to provide an overview of pub-
lished clinical studies evaluating the benefits of PBT. Specifically
this review examines the methodology used in clinical trials with
respect to study design and endpoints in an effort to highlight to
a predominantly non-proton clinical audience both the weak-
nesses in the existing evidence and the need for high quality ran-
domised trials.2. Methods
2.1. Search strategy and selection criteria
Electronic systematic searches were conducted in PubMed,
Embase and Cochrane databases for published clinical studies
where PBT was a therapeutic intervention for cancer conditions.
Search terms included proton beam therapy, cancer, carcinoma,
and various anatomical regions and tumour sites. These terms
were combined in accordance with the search platform for each
database. The search was limited to human studies in PubMed
and Embase but there were no date restrictions. The search strat-
egy used in each database is presented in the supplementary
appendix (A.1). The database search was conducted in August
2017, and was later updated in PubMed in July 2018.
Inclusion criteria were clinical studies where PBT was a thera-
peutic intervention for cancer, all comparative (randomised and
non-randomised) and non-comparative studies having one or more
treatment arms and prospective and retrospective studies. The lat-
ter were included in order to provide a comprehensive overview of
study designs used in various disease sites indicated for PBT. Sys-
tematic reviews were included at the screening stage, and the main
texts and references of these were searched in order to capture any
further eligible primary studies that were not included in the data-
base search, but were not included in this review.
Exclusion criteria included case reports, studies regarding PBT
intervention for non-cancer conditions, histopathology, and those
which predominantly focused on PBT treatment planning optimi-
sation, dosimetry and techniques. Other exclusions were studies
regarding cost-effectiveness of PBT, reports by health committees
or government bodies, systematic reviews and non-clinical reviews
on geographical distribution of PBT treatment centres and uptake.Abstracts and protocols were excluded, as these were not compa-
rable with the full texts of eligible studies at the same level of
detail. Although there were no language restrictions in the data-
base search strategy, non-English language studies for which trans-
lations could not be accessed were excluded.
One reviewer conducted the database search and screened the
articles for eligibility. A second reviewer independently screened
a random sample (20% (44/219)) of articles to confirm eligibility.
The reviewers discussed and resolved by consensus any disagree-
ments on inclusion and exclusion of studies. Titles and abstracts
were screened, the full texts of eligible studies were retrieved,
and systematic reviews were searched for eligible studies. The
search strategy is presented in Fig. 1 in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [29].2.2. Data extraction and synthesis
Data were extracted using a template in Microsoft Excel
(Table A.1, supplementary appendix). Data are presented graphi-
cally and using descriptive summary statistics. All analyses were
performed using Stata v13.0 [30].3. Results
In total, 3254 articles were identified. After duplicates were
removed, titles and abstracts of 3132 records were screened for eli-
gibility. Eighty-six percent (n = 2705) of articles were excluded at
this stage, themajority ofwhichwerenon-PBTandnon-cancer stud-
ies (n = 2154). Full texts of 427 articles (226primary studies and 201
systematic reviews) were screened to further identify eligible stud-
ies. Of these, 219 peer reviewed studies (excluding abstracts and
protocols) published between 1979 and 2018 were included.
Prospective and retrospective studies comprised 41% (89/219)
and 59% (130/219) of studies respectively (Fig. 2). Retrospective
data were obtained from patients’ medical records in 90%
(117/130) of cases, cancer database/registry in 6% (8/130), or past
prospective study data in 1.5% (2/130); sources were not stated
in 3/130 (2%) studies. The median (range) sample size for retro-
spective studies was 53 (6–243,822) and 51 (3–1447) for prospec-
tive studies (phase I/feasibility/pilot: 20 (8–211); phase I/II: 25
(12–202); phase II: 59 (23–393); phase III: 188 (151–202); obser-
vational: 51 (3–1447)) (supplementary appendix Figs. A.1–A.2).
Table A.2 (supplementary appendix) presents details of all studies
included in this review.
Fig. 3 shows the distribution of various designs used in the
included studies. Of the prospective studies, just 5/89 (6%) and
3/89 (3%)were randomisedphase II and III trials respectively. Table1
shows the details of RCTs, which involved PBT. The highest propor-
tionof prospective studieswere observational (52%; 46/89), and11%
(5/46) of thesemade comparisons between treatment arms. In three
prospective studies (Sejpal 2011, Hoppe 2014 and Blanchard 2016),
comparisons weremadewith historical control data on clinical out-
comes of intensive modulated radiotherapy (IMRT).
PBT was administered to adults, children or both in 54%
(118/219), 8% (17/219) and 24% (53/219) of studies respectively
and the ages of all patients ranged from one month to 95 years.
Fig. 4 shows the distribution of treated tumour sites by adults
and children. The ages of patients were not reported in 5%
(12/219) of studies and it was not possible to determine the age
range in 9% (19/219) of studies as these reported only the esti-
mated mean or median.
Direct comparisons between treatment effects of PBT and pho-
tons were investigated in 7% (6/89) of prospective studies
(Table A.3, supplementary appendix). Other cancer treatment
Fig. 1. Flowchart of search strategy in accordance with PRISMA statement. Abbreviations: PBT Proton beam therapy; PRISMA = Preferred Reporting Items for Systematic
Reviews and Meta-Analyses.
Fig. 2. Distribution of prospective and retrospective studies by year of publication
(n = 219).
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protons were chemotherapy, carbon ions, transarterial chemoem-
bolization, and transpupillary thermotherapy. PBT alone or in com-
bination with other therapies was administered in treatment of
cancer of the breast (7/219), CNS (37/219), blood (1/219), bone
(2/219), gynaecological organs (4/219), gastrointestinal tract
(26/219), head and neck (40/219), eye (47/219), prostate
(28/219) and soft tissue (3/219). Fig. 5 shows the distribution of
phase II and III trials by disease site treated by PBT.3.1. PBT centres – location and collaboration
A high proportion of prospective studies (90%; 80/89) and 75%
(18/24) of phase II and III trials were conducted at single PBT cen-
tres. In most studies, it was not possible to ascertain patterns of
referral to the PBT study centres. The countries with the highest
number of published studies were the United States (120/219
Fig. 3. Distribution of study designs used in included studies.
Table 1
Details of phase II and III randomised controlled trials that involved PBT (n = 8).
Authors, year Condition Aim RCT phase Age range (years) Sample size
Bush et al, 2016 [31] Hepatocellular carcinoma To report interim analyses of PBT versus
transarterial chemo-embolization
Phase 2 Not stated 69
Desjardins et al, 2006 [32] Uveal melanoma To determine the effect of systematic
transpupillary thermotherapy after PBT
Phase 3 22–88 151
Gragoudas et al, 2000 [33] Choroidal melanoma To determine the effect of a reduction in PBT
dose from standard 70 CGE to 50 CGE on
treatment outcomes
Phase 3 19–86 188
Habl et al, 2016 [34] Prostate cancer To explore the safety and feasibility of primary
hypofractionated irradiation with PBT and
carbon ions in a raster scan technique
Phase 2 40–80 92
Kim et al, 2013 [35] Prostate cancer To investigate the feasibility of
hypofractionated PBT in treatment of prostate
cancer
Phase 2 44–85 82
Liao et al, 2018 [36] Non–small cell lung cancer To compare outcomes of passive scattering PBT
versus IMRT
Phase 3 33–85 149
Shipley et al, 1995 [37] Prostate cancer To evaluate the possible increased efficacy of a
higher dose of radiation on the local recurrence
rate and patient survival
Phase 3 46–85 202
Zietman et al, 2010 [38] Prostate cancer To test the hypothesis that increasing radiation
dose improves clinical outcomes
Phase 2 45–91 393
Abbreviations: RCT = Randomised controlled trial; PBT = Proton beam therapy; IMRT = Intensive modulated radiotherapy; CGE = Cobalt gray equivalent.
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15 prospective, 34 retrospective) and France (16/219 studies; 5
prospective, 11 retrospective) (Fig. 6).3.2. Publications of prospective and retrospective studies
The highest proportion of studies were published between 2010
and 2014 (42% (93/219; 41 prospective, 52 retrospective)) (Fig. 2).
The observed increase in number of publications between 2009
and 2014 is likely due to the development of new proton centres
from 2006 particularly in United States [39]. Nineteen percent
(25/130) of authors of retrospective studies made recommenda-
tions about the need for studies with prospective designs; the
number of retrospective studies appears to have increased over
time.3.3. Outcomes
Patient reported outcome measures (PROMs), overall survival
and clinician assessed acute and late toxicity rates were collected
prospectively in 19 (21%), 55 (62%), 75 (84%) and 64 (72%) of the
89 prospective studies respectively either as primary or secondary
endpoints.
A primary endpoint was not defined in 56% (24/43) interven-
tional studies. Two of three phase III studies, 13/21 phase II studies,
3/11 phase I/II studies and 1/8 phase I/feasibility/pilot studies
defined a primary endpoint (n = 16) and/or powered their studies
for a specific outcome(s) (n = 3). Of the different types of primary
endpoints defined, nine were toxicity related (acute (n = 4), late
(n = 2), undefined assessment period (n = 3)), and four were effi-
cacy related (progression-free survival (n = 2), overall survival
(n = 1), local failure (n = 1)). Composite/co-primary endpoints were
defined in six studies and these included toxicity and feasibility of
Fig. 4. Distribution of disease sites in adult and paediatric patients (n = 188). Abbreviation: CNS = Central nervous system.
Fig. 5. Distribution of phase II and III trials by disease site treated by PBT (n = 24). Abbreviation: CNS = Central nervous system.
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control (n = 3) and disease-free and overall survival (n = 1).
Acute and late toxicity criteria used were Common Terminology
Criteria for Adverse Events (CTCAE), Radiation Therapy Oncology
Group (RTOG) toxicity grading, Late Effects Normal Tissue Task
Force (LENT), Late Effects Normal Tissue Task Force-Subjective,
Objective, Management and Analytic (LENT-SOMA), and Brock oto-
toxicity grading scale. Sixteen different questionnaires were used
to assess PROMs (supplementary appendix A1.4). The authors of
a case matched study, which aimed to compare the clinical out-
comes of IMRT and intensity modulated proton therapy (IMPT) in
head and neck cancer patients, suggested that PROMs should be
the measure of interest in proton studies [40].3.4. Follow up post-treatment
Ninety percent (79/89) of prospective studies reported duration
of follow up and this ranged from 4 days to 191 months
(observational: 4 days  191 months; phase I/feasibility/pilot:
2–97 months; phase I/II: 2–104 months; phase II: 2–150 months;
phase III: 3 – 139 months). In 38% (34/89) of prospective studies,
the authors recommended an increase in length of follow up in
patients treated with PBT. In particular, 21% (19/89) of authors sug-
gested the need to study long-term and late toxicities to enable
assessment of the patterns and severity of these outcomes. In one
study, the authors noted that clinical benefits of improved dosime-
try of PBT based on toxicity assessments may not be evident in the
Fig. 6. Distribution of geographical location of PBT treatment centre (n = 219). Abbreviation: PBT = Proton beam therapy.
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meaningful differences in clinician and patient reported toxicity
over time [41]. In addition, authors emphasized the need for longer
follow up to enable assessment of late radiation sequelae that may
occur many years after treatment [42] and the need to assess long
term QoL outcomes data [43]. Gardner et al [44] noted the potential
for recall and selective biases in the long-term assessment of QoL in
patients treated with high dose radiation techniques.
3.5. Randomisation
Allocation to treatment arms in the randomised studies was by
the simple randomisation method in 2/8 phase II/III studies and the
stratified randomisation method in 4/8 studies. The Zelen design
was used in one study and this involves randomising patients to
treatment groups before obtaining consent. In a further RCT,
patients were assigned to treatment groups by means of a Bayesian
adaptive approach which relies on event information being
updated in real time such that the ratio of allocation to treatment
arms can be adjusted before the next patient is randomly assigned
[36]. Intention-to-treat (ITT) analysis, i.e. analysing data according
to the groups to which the patients were enrolled and randomised,
was reported in 3/5 and 2/3 randomised phase II and III trials
respectively, while the other RCTs (n = 3/8) did not state whether
or not this approach was used.
3.6. Reporting
Eighty-seven percent (191/219) of studies reported eligibility
criteria. Approximately 11% (24/219) of all included studies did
not state the statistical methods used in analysing the study data
and 66% (31/43) of interventional studies did not state the justifi-
cation for the sample size used. It was not possible to determine
the estimated proportion of studies that involved a methodologist
because this information was not published in all studies. A high
proportion (88%; 78/89) of prospective studies assessed acute
(75/89) and/or late (64/89) toxicities as either primary or sec-
ondary outcomes. Of these, 22% (17/78) did not state the grading
criteria/system used. In addition, there was no definition for time-
lines of acute and late toxicity assessment in 67% (50/75) and 72%
(46/64) of studies respectively. Timeline definitions for acute toxi-cities ranged from 2 weeks to within 90 days after completion of
radiotherapy treatment. For late toxicity, this was >90 days.
One prospective study (multicentre, phase II) investigating clin-
ical outcomes from PBT in prostate cancer reported conducting
quality assurance assessment [45]. However, it is unclear whether
this was performed in other studies.
3.7. Limitations reported in retrospective studies
Thirty-eight percent (49/130) of retrospective studies reported
limitations of this study design and these include the constraint
on the types of data that can be extracted which may possibly
impede the extraction of complete data [39]. The authors of a large
retrospective study (n = 243,822), which compared protons with
photons using data from the National Cancer Database (NCDB), sta-
ted that a major limitation was the lack of both acute and late tox-
icity data [46]. Other retrospective studies reported that this puts a
restriction on the types of analysis that can be reliably performed
such as the comparison of toxicity rates between PBT and photons,
assessment of patient reported outcomes, and differences in peri-
ods of diagnosis and treatment.
Other limitations cited include the potential of biases, such as
selection bias (e.g. exclusion of patients with short follow up),
under- or over-reporting of specific outcomes or toxicities, small
sizes of patient cohorts in case series. In addition, difficulty in com-
paring findings with those of past studies due to limited informa-
tion about treatment regimen, differences in treatment protocols
or modifications in treatment delivery technique.
3.8. Limitations reported in prospective studies
Of the randomised phase II and III trials, 4/8 studies reported
limitations. These included small sample sizes, short follow up per-
iod and the lack of comparison with other conformal techniques in
one study [38] which compared conventional dose with high dose.
Similarly, short follow up was reported as a limitation in 2/8 phase
I/feasibility/pilot studies. For 50% (8/16) of the non-randomised
phase II studies, shortcomings were either limited availability of
PBT centres due to high costs of set-up, short follow up, small sam-
ple sizes, the lack of a photon control arm, or differences in specifi-
cations of PBT centres between participating institutions. Other
M. Ofuya et al. / Clinical and Translational Radiation Oncology 19 (2019) 17–26 23limitations were the heterogeneity in the patient population and
inconsistency in the number of proton beam fields used across
patients. In a phase I/II study, technical limitations such as machine
time constraints and the use of a single beam rather than multiple
beams were reported [47], and in a further study [48], comparison
with retrospective data on IMRT was stated as a limitation.4. Discussion
The aim of this systematic review was to provide an assessment
of the methodology used in clinical studies investigating PBT with
respect to study designs, outcomes, reporting of findings and limita-
tions. As the development of PBT services increases, it is imperative
to demonstrate and evaluate the key anticipated benefits, or lack of
benefits of PBT. There is a need to maintain equipoise and restrict
bias particularly as standard photon technologies are constantly
improving resulting in more conformal techniques [48]. To our
knowledge, this is the first systematic review of the methodology
used in clinical studies evaluating the benefits of PBT. Several sys-
tematic reviews have assessed the landscape of ongoing/recently
completed observational and/or interventional PBT trials including
phase II/III trials on PBT [49–51]. Verma et al [52] reviewed patient
reported outcomes,with a focus onQoL in patients treatedwith PBT,
the implications of these on cost effectiveness for stakeholders,
value based oncology (VBO), and trial design. As further prospective
clinical studies are developed, robust methodology in trial design,
analysis and reporting will be pivotal in influencing the clinical
management of cancer patients treated with PBT.
Our findings show that there is very limited level 1 evidence for
the use of PBT, as only 3% (3/89) of published proton studies were
phase III randomised controlled trials, despite the steady increase
in treatment uptake, across various tumour sites between 1979
and 2018. Strengthening alliance between referral centres and pro-
ton centres may positively influence patient recruitment, and
enhance opportunities for extensive and/or targeted clinical and
translational research. Although a wide range of sample sizes
was observed across the study designs of prospective studies, only
one phase III study had > 200 patients, and ‘small’ sample size was
cited as a limitation in prospective studies. Adequate sample size,
statistical power and optimally designed studies are needed to
ensure that the key research question(s) are addressed. The sub-
stantial increased capital cost, workforce requirements and the
need for high quality evidence to make the case for health care sys-
tem and insurer funding, requires high-level prospective evidence
including randomised trials. This review suggests the need for sub-
stantial improvement in study design funding and delivery of
future trials.
In addition, this review shows a particularly disappointing and
significant concern; the paucity of patient reported outcome data
as well the growing need for resources to capture late toxicity data
beyond the primary analysis stage of the study. There is also the
need for improved standard reporting of study design and out-
comes in order to enable reproducibility, repeatability and compa-
rability across similar patient cohorts.4.1. Randomised trials in PBT
Only 9% (8/89) of the prospective studies included in this
review randomised patients and of these RCTs, only one study
compared protons with standard photon therapy. This finding res-
onates with the results of previous clinical reviews regarding the
lack of high-level clinical evidence for PBT in several indications
[53,54] and further highlights the need for more randomised trials
comparing PBT with standard photon therapy in adult patients. In
the randomised phase II trial [36] of non-small cell lung cancer, nosignificant differences were observed in toxicity rates between
passively scattered proton therapy (PSPT) and IMRT. Several possi-
ble reasons were suggested for the study’s findings [22] and these
have raised further discussions and debate about the clinical
advantages of PBT in the treatment of NSCLC. Although the trial
used passively scattered proton beams, whether the use of a more
advanced treatment planning technology such as pencil beam
scanning or IMPT would have produced different results is
unknown. This raises the issue of optimised old technology versus
sub-optimal new therapy. The comparative effect of PBT to stan-
dard photons using meaningful endpoints is of crucial interest to
stakeholders including patients, clinicians and financiers of PBT
centres, particularly with advances in other radiotherapy modali-
ties such as IMRT and stereotactic body radiation therapy (SBRT)
and with the high cost of PBT [55,56].
There is expert consensus that randomised proton trials in pae-
diatrics would be unethical as the benefits are substantially greater
allowing reduction in the risk of secondary cancers [57] and radia-
tion effects on tissue growth and functional development
[15,58,59]. Where it may be impractical to conduct randomised tri-
als, well-designed prospective cohort studies may provide valuable
insight in quantifying the advantage and developing strategies to
mitigate or limit the disadvantages of PBT as patients can be moni-
tored and any adverse events/reactions can be managed as they
occur [59].
The number of retrospective studies appears to have increased
over time and 19% (25/130) of authors of retrospective studies rec-
ommended the need for prospective analyses. Although the analy-
sis of retrospective data may appear attractive due to the
theoretical ready availability of data, without the additional cost
of, and delays in, setting up a study or the barriers to recruiting
patients prospectively, there are, however, methodological and
technical disadvantages. These include access to complete data,
differences in pre-treatment assessments, changes in treatment
planning techniques over time, advances in treatment delivery
technology (such as from passively scattered to pencil beam scan-
ning), differences in treatment time-periods, and the heterogeneity
of patient populations.
Moreprospective studies, especiallywell designed robust clinical
trials in PBT are needed. The UK Proton Beam Clinical Trial Strategy
Group has outlined an eight–point framework to support the devel-
opment and delivery of high-quality clinical trials [60]. Statistical
and clinical considerations on RCT design should include restriction
of patient selection bias due to tumour characteristics, physician
judgement and patient preference.When designing phase II studies,
efficient strategies to utilize evidence gained in phase II and transi-
tion to definitive phase III evaluation should be developed.
Less than 50% (19/43) of the interventional studies reported a
primary endpoint and specifically, just 13/21 phase II trials and
2/3 phase III. In selecting a primary endpoint consideration should
be given to the level of evidence required to influence clinical prac-
tice. Of the primary endpoints reported, the majority were toxicity
related although definitions, including assessment periods were
variably reported, making replication challenging. No studies had
PROMs as a primary or co-primary endpoint. Failure to define the
primary endpoint/objective of a study makes evaluation of its suc-
cess/failure prone to subjectivity and bias.
4.2. Collaboration between treatment centres
The majority of phase II and III trials were conducted in single
PBT centres and small sample size was cited as a limitation in stud-
ies included in this review. Increased collaboration between PBT
centres and referring photon centres would increase access to
treatment and enrolment in trials. This may result in a more repre-
sentative study sample, increased variability and power, which
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ing population. Increased national and international collaboration
during the planning and design stages of proton trials would fur-
ther facilitate and strengthen the combination of results from sev-
eral studies in a systematic review and/or meta-analysis as
appropriate. Other challenges reported by authors include the high
cost of setting up proton treatment facilities, which limits its avail-
ability, and the logistical considerations involved in patients trav-
elling long distances to receive treatment. In the clinical trial
setting, the impact of these will need to be considered in the design
and conduct of the study. Although evidence suggests that patients
are willing to travel to receive treatment [27], issues with cost cov-
erage, support systems for patients when receiving treatment far
away from home and the temporary absence of the familiar care
team will need to be addressed.
4.3. Patient reported outcomes
Patient reported outcomes are progressively becoming a focal
point in evaluating the effects of new interventions in health
research, thus increasing awareness about the importance of
obtaining patients’ perspectives during treatment and follow
[61]. PROMS are assessed using QoL questionnaire scales and/or
interviews in order to obtain a comprehensive evaluation of the
patient’s QoL. Only 21% (19/89) of prospective studies in this
review reported inclusion of PROMs as either a primary or sec-
ondary endpoint. For PBT, assessing QoL as a hypothesised benefit
would provide information on the patient’s experience which con-
sequently influences clinical decision-making in providing a holis-
tic management protocol and improving the quality of patient care
during and after treatment.
4.4. Increase in length of follow up
More than 30% (34/89) of authors have made recommendations
for increased follow up duration to enable assessment of long term
and late toxicities. This raises several questions about how to
implement this in clinical practice: (a) what increase in length of
follow up will significantly affect patient management and QoL
from the clinician’s and patient’s perspectives?, (b) how will the
collection and analyses of these data, such as PROMs using ques-
tionnaires, be performed? Notably, the answers to these will
depend on several factors including the standard management pro-
tocol for the tumour site, characteristics of the patient cohort,
funding platforms, human resources and accessing the required
infrastructure. Given that one of the key predicted benefits of
PBT is its effect on patient QoL in the short and long term, it would
be important to have strategic deliberations on how long term fol-
low up of patients may be achieved.
4.5. Radiotherapy quality assurance
Quality assurance procedures for radiotherapy clinical trials is
recommended as this ensures alignment of specifications and
enhances protocol adherence across participating sites, which con-
sequently ensures reliability of trial results [62,63]. The interna-
tional collaboration of radiotherapy trials quality assurance
(RTQA) groups around the world (Global Clinical Trial RTQA Har-
monization Group) is well established and it is expected that PBT
trials will employ these services during trial development and
conduct.
4.6. Reporting of methods and findings
Comprehensive reporting of methods and findings are essential
in order to ensure comparability between studies and enable evi-dence synthesis in systematic reviews andmeta-analyses. The clin-
ical and statistical considerations used in the design of the trial
should be fully reported as this provides information on the robust-
ness of themethodology and allows replication. Approximately 20%
(17/78) of the included studies did not state the criteria used in the
assessment of toxicities and more than 60% (50/75) did not state
reporting timelines. Toxicity assessment is considered an impor-
tant outcome in assessing the benefits of PBT, and several criteria
are used in grading the observed clinician and patient reported
adverse events. It is important that these are reported as the find-
ings of a study informs clinical practice in decision making, patient
management protocols during follow up andmay influence policies
on a broader scale. Standardised reporting of outcomes of interven-
tional and observational studies in radiotherapy studies is needed.
To address this, we suggest the development of a core or minimum
outcome data set for PBT studies and/or the extension of the CON-
SORT statement [64] for use in radiotherapy RCTs.
We have combined phase I, feasibility and pilot studies for the
purpose of this review as these design terms are used inconsis-
tently in the literature. The framework on reporting of pilot and
feasibility recommends clarification of the design with inclusion
of these in the titles and/or abstracts [65].
Although our literature search has been thorough, it is not
exhaustive and there were limitations in conducting this review.
We did not include studies that were not published in the English
language due to limited resources and in this way may have
missed further eligible studies. In addition, we excluded published
abstracts for which there were no corresponding full texts such as
conference proceedings in order to ensure that all included articles
were assessed on an equal basis. The treated tumour sites are not
discussed individually as this was not within the scope of this
review.
We have provided an overview of the study designs used in
assessing the benefits of PBT in the treatment of various disease
sites for adult and/or paediatric cohorts at PBT centres located
across the world. Our findings highlight some of the challenges
and limitations encountered in conducting these studies as well
as the level of collaboration between PBT centres and other refer-
ring treatment centres. Furthermore, we have demonstrated the
need for patient reported outcomes and long-term toxicity assess-
ments in the evaluation of PBT.
With the development and inception of two NHS proton centres
in the UK, and given the country’s record of accomplishment in
conducting internationally practice-changing trials [66], there is
an obligation to answer the question as to whether the dosimetric
benefits of PBT translate into meaningful clinical benefits [67]. To
maximise this opportunity, trials evaluating the effects of PBT must
be of the highest quality, and should be designed in conjunction
with experts in methodology, with reference to the points raised
above. The challenge to the international radiotherapy research
community is to deliver a broad portfolio of clinical trials that
answer both clinical and translational research questions. This
must include, wherever feasible, randomised designs to provide
the highest level evidence possible. This will be achieved through
a combination of studies in individual countries and through inter-
national participation.5. Conclusions
Our findings clearly show there is limited randomised evidence
for PBT and hence there is a need for further randomised trials to
allow a robust assessment of the benefits of PBT. The development
and inception of further PBT services across the globe provides an
opportunity for well-designed prospective studies, including RCTs,
and we recommend that researchers seek methodological input
M. Ofuya et al. / Clinical and Translational Radiation Oncology 19 (2019) 17–26 25and support from clinical trial units in the design, development
and throughout the course of the trial.
Infrastructure and resources to facilitate collection of long-term
outcome data including QoL and late toxicities in cancer patients
treated with PBT is recommended.
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